Focus: Enveda Biosciences is a Boulder-based biotech company pioneering AI-driven small molecule drug discovery from plant-derived compounds. The company operates as a publicly listed entity focused on immunology, neurology, respiratory, and gastroenterology indications.
Profile data last refreshed 3m ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
7 added, 8 removed. Backfill posture.
Best for early-career scientists and platform builders seeking equity upside in an AI-discovery innovator with fresh capital; higher risk for those prioritizing near-term product revenue or established organizational maturity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Enveda Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Enveda Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Enveda Biosciences: $311 Million Series E Fuses Ancient Wisdom With AI-Powered Drug Discovery - Vocal
Enveda Biosciences: $311 Million Series E Fuses Ancient Wisdom With AI-Powered Drug Discovery Vocal
Enveda raises $311M Series E to scale AI drug discovery - Dealroom
Enveda raises $311M Series E to scale AI drug discovery Dealroom
AI drug-discovery firm Enveda raises $311M - BizWest
AI drug-discovery firm Enveda raises $311M BizWest
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push - BioSpace
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push BioSpace
Enveda, an AI drugmaker, banks $311M in venture funding - BioPharma Dive
Enveda, an AI drugmaker, banks $311M in venture funding BioPharma Dive
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo